NCT00516828View on ClinicalTrials.gov

Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 27, 2007

Primary Completion Date

March 18, 2010

Study Completion Date

January 10, 2013

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

cytarabine

subcutaneously twice daily from Day 1 to 10

Trial Locations (4)

B3H 1V7

QEII Health Sciences Center, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

H2W 1S6

McGill University - Dept. Oncology, Montreal

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

NCIC Clinical Trials Group

NETWORK

NCT00516828 - Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter